NXTC Stock Analysis: Buy, Sell, or Hold?
NXTC - NextCure, Inc. Common Stock
$7.83
-2.37 (-23.24%)
▼
5d:
-19.61%
30d:
-36.85%
90d:
-40.77%
WAIT
LOW Confidence
Analysis Updated: May 22, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Get Alerted When NXTC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NXTC is down 19.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NXTC is down 19.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NXTC is currently trading at $7.83, which is considered oversold relative to its 30-day fair value range of $8.96 to $10.94.
Technical Outlook: Technically, NXTC is in a strong downtrend. The price is currently testing key support at $8.81. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 23.2% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $19.33 (+146.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NXTC is in a strong downtrend. The price is currently testing key support at $8.81. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 23.2% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $19.33 (+146.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$8.96 -
$10.94
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-23.2%)
- BULLISH: Trading 146.9% below Wall St target ($19.33)
- WARNING: Recommendation downgraded due to -19.6% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$8.96 -
$10.94
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$8.81
Resistance Level
$11.14
Current Trend
Strong Downtrend
Technical data as of
May 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.94
Wall Street Target
$19.33
(+146.9%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: May 26, 2026 1:13 AM ET
Data refreshes hourly during market hours. Next update: 2:13 AM
Data refreshes hourly during market hours. Next update: 2:13 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NXTC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 61 BUY |
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 48 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 57 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 56 HOLD |
